BABAM2

Across TCGA pan-cancer cohorts, BABAM2 Mutation is linked to patient survival in 6 of 34 cancer types, making it a survival-associated BABAM2 data layer compared with 22 for mass-spec protein and 4 for mass-spec protein.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher BABAM2 Mutation is associated with better overall survival. In most high-consensus cancer types, elevated BABAM2 expression acts as an unfavorable survival marker, although some lineages such as LUAD and STAD show a favorable association.

LUAD, SKCM, and CESC are the cancer types where BABAM2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	OS	Median	All	0.504	0.368	.004	9	view →
SKCM	DFS	Median	IV	0.036	0.433	<.001	9	view →
CESC	OS	Median	III,IV	0.167	0.657	.044	6	view →
UCS	DFS	Median	All	0.136	0.523	.034	6	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →
STAD	DFS	Median	III,IV	1.000	0.297	.048	1	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

BABAM2–LUAD (OS)

Open the LUAD breakdown →